tiprankstipranks
Compass Therapeutics, Inc. (CMPX)
NASDAQ:CMPX
US Market
CMPX
Compass Therapeutics
RESEARCH TOOLSreports
Want to see CMPX full AI Analyst Report?

Compass Therapeutics (CMPX) Stock News & Sentiment

553 Followers
Compass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
Premium
Ratings
Compass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
3d ago
CMPX
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
Premium
Ratings
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
20d ago
CMPX
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
Premium
Ratings
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
28d ago
CMPX
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
Premium
Ratings
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
28d ago
CMPX
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
Premium
Company Announcements
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
28d ago
8K
CMPX
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
Premium
Ratings
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
2M ago
CMPX
Buy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer
Premium
Ratings
Buy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer
2M ago
CMPX
More CMPX News >

CMPX News on the Web

Canaccord Genuity Sticks to Their Buy Rating for Compass Therapeutics (CMPX)
TipRanks News
Bullish
Compass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Guardant Health (GH) and Compass Therapeutics (CMPX)
TipRanks News
Neutral
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX)
TipRanks News
Bullish
Buy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Maze Therapeutics, Inc. (MAZE) and Compass Therapeutics (CMPX)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Compass Therapeutics (CMPX) and Talphera (TLPH)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
CMPX
Sector Average
Media Buzz
This Week2 articles
Weekly Average8 articles
News Sentiment
This Week99%
Sector Average80%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CMPX’s Media Buzz Sentiment?
2 articles about CMPX were published this week. In an average week, 8 articles are published.
    What is CMPX’s weekly average amount of articles?
    In an average week, 8 articles about CMPX are published.
      What is CMPX’s News Sentiment?
      99% of articles about CMPX were positive this week, compared to its sector average of 80%.
        Healthcare Stocks that are Trending in the News
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        TLSATiziana Life Sciences
        JUNSJupiter Neurosciences, Inc.
        IMMXImmix Biopharma
        Showing the stocks with the most bullish news sentiment over the past week